In last trading session, Viracta Therapeutics Inc (NASDAQ:VIRX) saw 1.05 million shares changing hands with its beta currently measuring 0.66. Company’s recent per share price level of $0.21 trading at -$0.01 or -4.22% at ring of the bell on the day assigns it a market valuation of $8.21M. That closing price of VIRX’s stock is at a discount of -523.81% from its 52-week high price of $1.31 and is indicating a premium of 38.1% from its 52-week low price of $0.13. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 5.85 million shares which gives us an average trading volume of 2.13 million if we extend that period to 3-months.
For Viracta Therapeutics Inc (VIRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.19 in the current quarter.
Viracta Therapeutics Inc (NASDAQ:VIRX) trade information
Upright in the red during last session for losing -4.22%, in the last five days VIRX remained trading in the green while hitting it’s week-highest on Wednesday, 12/18/24 when the stock touched $0.21 price level, adding 8.7% to its value on the day. Viracta Therapeutics Inc’s shares saw a change of -63.77% in year-to-date performance and have moved 17.53% in past 5-day. Viracta Therapeutics Inc (NASDAQ:VIRX) showed a performance of 37.67% in past 30-days. Number of shares sold short was 2.69 million shares which calculate 1.85 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 97.38% to its current value. Analysts have been projecting 8 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -3709.52% in reaching the projected high whereas dropping to the targeted low would mean a loss of -3709.52% for stock’s current value.
Viracta Therapeutics Inc (VIRX) estimates and forecasts
Statistics highlight that Viracta Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -63.71% of value to its shares in past 6 months, showing an annual growth rate of 39.39% while that of industry is 16.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 44.96% during past 5 years.
Viracta Therapeutics Inc (NASDAQ:VIRX)’s Major holders
Insiders are in possession of 2.84% of company’s total shares while institution are holding 50.06 percent of that, with stock having share float percentage of 51.52%. Investors also watch the number of corporate investors in a company very closely, which is 50.06% institutions for Viracta Therapeutics Inc that are currently holding shares of the company. BVF INC/IL is the top institutional holder at VIRX for having 3.61 million shares of worth $1.97 million. And as of 2024-06-30, it was holding 9.192 of the company’s outstanding shares.
The second largest institutional holder is CITADEL ADVISORS LLC, which was holding about 1.52 million shares on 2024-06-30. The number of shares represents firm’s hold over 3.8659 of outstanding shares, having a total worth of $0.83 million.
